Covance’s France- and U.K.-based facilities will conduct discovery and early development studies for Inserm, its subsidiary, and startups within Inserm Transfert Initiative’s portfolio. The startups will also gain access to Covance’s scientific, operational and program management expertise.
Covance experts will advise representatives from Inserm Transfert and Inserm Transfert Initiative to help select projects that will most benefit from Covance’s drug discovery and drug development capabilities.
“The robust resources Covance brings will help our startup companies grow more quickly and efficiently,” said Matthieu Coutet, investment director of Inserm Transfert Initiative. “Covance will provide important strategic guidance to help them establish and implement early clinical development plans with the right technical know-how and management support.”
